IPOPI attends event on Cross-border Cooperation to Support Equitable Access to Advanced Therapies
IPOPI was pleased to attend on 10 November the online event hosted by the European Alliance for Transformative Therapies (TRANSFORM) MEP Interest Group to discuss ‘How to Optimise Cross-border Cooperation to Support Equitable Access to Advanced Therapies’. Experts and policy-makers gave consideration on how to adapt the current legislative framework and upscale the European infrastructure to overcome the current access challenges to ATMPs and to secure equitable delivery and reimbursement of these treatments in the EU.
Advanced Therapies Medicinal Products (ATMPs) are highly personalised treatments with the potential to transform the lives of patients. Due to their complex manufacturing and distribution processes, the need for trained healthcare providers and/or the rarity of the condition they aim to address, many of these therapies are only available in a small number of treatment centres in Europe. As a result, many European patients may need to travel cross-border to benefit from treatment with a transformative therapy. The European legislative provisions for patients to access healthcare abroad and have the costs covered by their national health insurance are insufficient to secure timely access to these transformative treatments. For more information see here.
This issue was also highlighted during IPOPI’s 18th PID Forum last July. For more information see here.
IPOPI is a member of the TRANSFORM, a multi-stakeholder Alliance that connects Members of the European Parliament (MEPs) and policy-makers with patient groups, medical experts and associations, scientists, researchers, industry actors, networks and other relevant stakeholders. TRANSFORM aims to foster effective dialogue and provide evidence-based policy recommendations to enable safe and timely patient access to cell and gene therapies, whilst ensuring the sustainability of healthcare systems.